BioStem Technologies Inc (PK) (BSEM) News

$BSEM Back over $20 next Week!

$BSEM Zacks: BSEM Continues to Exceed Expectations
https://scr.zacks.com/news/news-details/2024/BSEM-Continues-to-Exceed-Expectations/default.aspx

Strong day yesterday +1.10 (+7.24%) ~ Very undervalued with all that is happening here! Nice afternoon move Thursday... Looking for continuation today...$BSEM

My personal goal here is 100% from here ~$15.25... That would be a huge gain... Looking 1-2 months for Target to hit...

$BSEM Continues to Exceed Expectations ~ Price Target Now $32.50
https://scr.zacks.com/news/news-details/2024/BSEM-Continues-to-Exceed-Expectations/default.aspx

We reiterate our belief the BSEM is still underpriced even after its recent move higher and continues to represent a good opportunity at recent prices for investors to get in before what we believe will be a more aggressive move higher in the not-too-distant future. The vision management has for the company’s products and the focus they are using to deliver results are encouraging and are now being rewarded by increased demand. As such, we urge investors to take a good look at BSEM.

$BSEM NASDAQ Up-listing just a matter of time! Application was filed in Sept so it should be approved any time now! The NASDAQ listing will allow may new Institutions to be able to buy $BSEM. That will be huge!

$BSEM Continues to Exceed Expectations ~ Upgrades Price Target ⚡️
https://scr.zacks.com/news/news-details/2024/BSEM-Continues-to-Exceed-Expectations/default.aspx

$BSEM Medicare Issues Shouldn’t Impact BioStem
https://finance.yahoo.com/news/bsem-medicare-issues-shouldn-t-160500411.html

We reiterate our belief in the direction of BSEM and urge investors to avoid succumbing to kneejerk responses and message board rumors. The vision and focus of BSEM is impressive and gives us confidence that BSEM will continue to have its products covered by Medicare and continue to grow its revenues.

Think we bounce soon here...

Looking for a nice rebound day here...$BSEM

$BSEM Zacks Increases Price Target to $32.50 Per Share. Very Undervalued Here!✈️

$BSEM Chart back on uptrend from recent lows. MACD crossed bullish yesterday and accumulation getting stronger. Investors are accumulating shares here! Looks headed back to recent highs. 📈

$BSEM BioStem Technologies: The Superior Stem Cell Investment Opportunity
Link: https://www.wallstreetpr.com/biostem-technologies-bsem-the-superior-stem-cell-investment-opportunity-58143?utm_medium=social&utm_source=twitter&utm_campaign=simplified&utm_content=simplified8b5cc

Bigger than normal volume.  News soon? 

Solid close Friday.  Looking for continuation 

New Growth Report BioStem Technologies, Inc. (OTC: BSEM)

BSEM Key Highlights


Completed an extensive two-year audit in preparation for moving BSEM to a national exchange. (NASDAQ or NYSE)
Recently released their Q1 earnings, which shocked the market with revenues totaling $41 million in the first quarter of 2024.
First positive net income of over $4.4 million in the quarter.
Analyst Target $23.75 representing a 153% upside from the current price of $9.38
Regenerative medicine leverages the body's natural systems to rebuild tissues and organs. It is expected to revolutionize healthcare, with the global stem cell market projected to reach $18.4 billion by 2028.

Take a minute to look at the full analysis and disclosures >>> https://tradersnewssource.com/wp-content/uploads/2024/06/TNS-BSEM-growth-report-6-27-24.pdf

#BioStem #BSEM #WoundCare #Biotech #Healthcare #StockMarket

I’m watching $BSEM, regenerative medicine is hot, the stock is cheap compared to peer group companies, read their research report here $SINGT $FFIE $SLNA $REBN $TTOO
https://s27.q4cdn.com/906368049/files/News/2024/Zacks_SCR_Research_05152024_BSEM_Sorensen.pdf

Nice chart

Where's this going?

Let's see that end of week surge today $

Let's see that bounce tomorrow $

Charts setting up nicely here imo

Volumes picking up $

Yep we're primed for it $

TRENDING STOCK CHART ANALYSIS



$BSEM

Go time imo

Nice movement today! Creeping towards those highs $

Top the morning $BSEM

3.50s + coming , clear skies when they fall

Absolutely! Solid close $

structured well so it can move fast

good target

Looking for that next leg up $ thru 3.40s

Seeing a nice little uptrend these past few months BSEM

Due for something

Fresh week

Think she ready

Overdue imo

Been quiet. Time to wake up?

Good Morning $BSEM

https://www.globenewswire.com/en/news-release/2022/08/22/2502499/0/en/BioStem-Technologies-Reports-Second-Quarter-2022-Operating-and-Financial-Results.html

Conference Call Details

Date: Monday, August 22, 2022
Time: 4:30 pm EDT
Webcast Link:
https://event.on24.com/wcc/r/3911284/BE0F9AAF8531A6FE6131F4DBA6ADCF55
Conference ID: 4373739
Participant Toll-Free Dial-In Number: 1 (888) 880-2204
Participant Toll Dial-In Number: 1 (646) 960-0414

$BSEM BioStem Technologies® CEO to Appear on the Benzinga All Access Show on June 17,2022Press Release | 06/17/2022

POMPANO BEACH, FLORIDA, June 17, 2022 (GLOBE NEWSWIRE) -- BioStem Technologies® (OTC: BSEM), a leading, innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies will be hosted on Benzinga’s All Access show, which airs on Benzinga TV and Benzinga’s YouTube channel on June 17 2022, at 10:20 AM EST.

BioStem Technologies CEO Jason Matuszewski will be interviewed and provide updates on the latest developments in BioStem’s business growth and portfolio of products. A link to the YouTube broadcast will be available in our investor relations news portal at the below link:

https://www.biostemtechnologies.com/news.

Or watch or listen live to the All-Access broadcast via the Benzinga YouTube channel in the link below:



About BioStem Technologies, Inc. (OTC PINK: BSEM): BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies. The Company is focused on manufacturing products that change lives, leveraging its proprietary BioRetain® processing method. BioRetain has been developed by applying the latest research in regenerative medicine, focused on maintaining growth factors and preserving tissue structure. BioStem Technologies’ quality management system and standard operating procedures have been reviewed and accredited by the American Association of Tissue Banks (“AATB®”). These systems and procedures are established per current Good Tissue Practices (“cGTP”) and current Good Manufacturing Processes (“cGMP”). Our portfolio of quality brands includes VENDAJE®, VENDAJE® AC, and VENDAJE® OPTIC. Each BioStem Technologies placental allograft is processed at the Company’s FDA registered and AATB accredited site in Pompano Beach, Florida.

Investor Relations:
info@biostemtech.com
(954) 380-8342

Here we go!!!!!!!!!

BioStem announced Q1 financial results

https://www.globenewswire.com/news-release/2022/05/16/2444189/0/en/BioStem-Technologies-Reports-March-31-2022-Record-Quarterly-Financial-Results.html

Are you selling Rick?

I am new here, looking at their revenue growth looks like they are only a skip and a jump away from a 50 million dollar valuation. Does anyone know why they do not trade much?

$BSEM BioStem Technologies, Inc. Awarded Q Code for VENDAJE® Product Line From CMS.
Press Release | 07/23/2021
Pompano Beach, Fl., July 23, 2021 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC PINK: BSEM) ("BioStem" or the "Company"), a pre-clinical-stage biotechnology company focused on harnessing elements of perinatal tissue for use in regenerative therapies; announces that the Centers for Medicare and Medicaid Services (“CMS”) has published a new code pursuant to the Company’s application for Healthcare Common Procedure Coding System (“HCPCS”) “Q” codes. The Company initially filed an application in July of 2020 to have CMS establish a new HCPCS Q code for VENDAJE® and has now received a favorable decision in July of 2021.

The HCPCS Q-code assigned to VENDAJE will be billed as Q4252, and will be effective October 1st, 2021. Q-Codes are established to identify drugs, biologicals, and medical equipment or services not identified by national HCPCS Level II codes, but for which codes are needed for Medicare claims processing. CMS, via its sub-committee, the HCPCS Committee, assigns Q-Codes based on the Committee's review and they are maintained by the HCPCS national panel, which is comprised of representatives from the Health Insurance Association of America, Blue Cross/Blue Shield, and CMS.

Jason Matuszewski, CEO of BioStem Technologies, states, "Establishment of a unique Q-code for VENDAJE is an integral building block to our growth and reimbursement strategy and will offer greater access to our tissue allografts for patients and providers through Medicare and the CMS system. We are excited about the opportunities that this new Q-code provides for our customers to now more appropriately bill and code for VENDAJE and we anticipate significant growth opportunities. We will continue to work to ensure we can deliver better outcomes that improve quality of life, reduce recovery times, and lower costs.”

About BioStem Technologies, Inc. (OTC PINK: BSEM): BioStem Technologies, Inc. is a pre-clinical-stage biotechnology company focused on harnessing elements of perinatal tissue and the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases. Our proprietary approach, called Local Microenvironment Activation®, or LMA®, uses combinations of small molecules, cytokines, and growth factors to activate the microenvironment within the body to create communication for repair in the tissue. BioStem Technologies offers a comprehensive portfolio of high-quality brands that include RHEO™, OROPRO®, VENDAJE®, VENDAJE AC®, and VENDAJE OPTIC®. The Company is comprised of a diverse group of scientists, physicians, and entrepreneurs who collaborate to create innovative products. These technologies improve the Quality of Life for our patients and, as a result, drive shareholder value.

Forward-Looking Statements: Except for statements of historical fact, the matters discussed in this press release are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "future," "plan" or "planned," "expects," believe" or "projected." These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company's control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing, exploiting and protecting proprietary technologies, intense competition and additional risks factors as discussed in reports filed by the company with OTC Markets.

BioStem Technologies, Inc.
Phone: 954-380-8342
Website: http://www.biostemtechnologies.com
Email: info@biostemtech.com
Twitter: @BSEM_Tech
Facebook: BioStem Technologies

Investor Relations:
info@biostemtech.com
(954) 380-8342

big ask someone hit that please!!